Social Europe

politics, economy and employment & labour

  • Themes
    • European digital sphere
    • Recovery and resilience
  • Publications
    • Books
    • Dossiers
    • Occasional Papers
    • Research Essays
    • Brexit Paper Series
  • Podcast
  • Videos
  • Newsletter

What when there’s a vaccine?

Stuart Blume and Maurizia Mezza 15th May 2020

Amid the accelerated scientific quest for a vaccine against the coronavirus, crucial ethical and social questions have not yet been addressed.

vaccine
Stuart Blume

Each day brings reports of progress toward a coronavirus vaccine. As millions struggle with separation, loss of income, isolation and fear for vulnerable loved ones, the prospect of a vaccine offers courage and hope.

Vaccination has indeed saved countless lives and has been a cornerstone of public health for more than half a century. Currently 120 candidate vaccines against the coronavirus are under development, of which eight have entered human trials. One or more will almost certainly become available—not this year, hopefully next. But what then?

vaccine
Maurizia Mezza

How the vaccine is to be deployed may seem a trivial question compared with the urgency of today. Just a few months ago the only vaccination-related concern seemed to be the reluctance of some parents to have their child vaccinated.

Nevertheless, the history of recent vaccination campaigns shows that introducing a new vaccine is rarely unproblematic. It is best to clarify potential problems before solving them becomes itself a matter of urgency.

Our job is keeping you informed!


Subscribe to our free newsletter and stay up to date with the latest Social Europe content.


We will never send you spam and you can unsubscribe anytime.

Thank you!

Please check your inbox and click on the link in the confirmation email to complete your newsletter subscription.

.

Two scenarios

When a vaccine is licensed, what are these problems likely to be? Over the months to come we can imagine two scenarios.

In the first, optimistic, scenario, a combination of hygienic, social and therapeutic measures will have brought the epidemic under control. There will be no dreaded ‘second wave’. When the vaccine becomes available, people will view Covid-19 as akin to the flu. In Europe, rates of vaccination against seasonal influenza among over-65s vary hugely between countries: from less than 20 per cent to nearly 80 per cent.

When the human papilloma virus (HPV) vaccine was introduced, not only were initial vaccination rates lower than expected but here too huge differences emerged between countries. In Scotland in 2012 86.4 per cent of the target population (of adolescent girls) were vaccinated, but in Greece only 9 per cent. This was partly explicable in terms of how vaccination was organised—school-based programmes achieved higher rates. But sometimes girls were cajoled, threatened or bullied into getting themselves vaccinated.

Will it matter if there is little demand for the vaccine? The answer depends on the coverage needed for ‘herd immunity’. If enough people are immune, whether from vaccination or recovery, circulation of the virus is restricted. Unvaccinated people are then protected. The threshold percentage varies from one virus to another and may be around 70 per cent for the SARS-CoV-2 virus. It does matter.

Reports of responses to current social-distancing rules give some idea of the groups in which coverage might be problematically low: young people who regard themselves as low-risk, whole regions in which the state is viewed with suspicion and communities cut off by language or detained in overcrowded refugee camps. If adequate coverage is not achieved, what then? What measure of compulsion is acceptable?


We need your support


Social Europe is an independent publisher and we believe in freely available content. For this model to be sustainable, however, we depend on the solidarity of our readers. Become a Social Europe member for less than 5 Euro per month and help us produce more articles, podcasts and videos. Thank you very much for your support!

Become a Social Europe Member

Supply outstripped

In a second scenario the epidemic will have re-emerged. People are again dying. Everyone is clamouring to be vaccinated.

But the new vaccine is expensive and there is too little of it. Most of the institutions with vaccines already in human trials are small biotech firms. Production will gear up gradually and for months international demand will outstrip supply. Poor countries with weak health systems will be pushed to the back of the queue—however great their need.

This is what happened with HPV vaccines when they first became available in 2006. Four-fifths of the women affected by an HPV-related disease live in low and middle-income countries. But at $360 per capita for the required three shots these countries could not afford the vaccines at the time.

The introduction of the H1N1 flu vaccine in 2009 is also illuminating. When H1N1 was declared a pandemic, advance purchase contracts were automatically activated. Wealthy countries had paid an annual subscription to maintain these, sometimes with more than one manufacturer. They then had prior claim on a limited supply, though still only part of what they had ordered. Many countries subsequently developed guidelines, anticipating a future influenza pandemic.

Under such guidelines, priority should be given to healthcare workers and to people at greatest medical risk—as in respect of the coronavirus epidemic. But where regional sentiments are strong the most affected regions might claim priority or, elsewhere, insist that supplies should be equitably distributed among regions.

What has to be avoided at all costs is the nationalistic pushing and shoving which has taken place in recent weeks over ventilators and diagnostic tests. Can acceptable rationing criteria be found, so political haggling is later avoided?

Contract secrecy

Experience with the H1N1 vaccine a decade ago highlights something else. Although not public knowledge at the time, it emerged that many contracts absolved manufacturers of any obligation in respect of vaccine-related complications or side-effects. And such complications did arise: in Sweden and Finland, for example, cases of narcolepsy were found to be associated with one of the influenza vaccines used to control the pandemic.

Three of the eight candidate vaccines now in human trials make use of genetic material from the virus. The underlying technology has never been proven in a licensed human vaccine. There will be pressure to fast-track a coronavirus vaccine. Since there will not have been time to test it in all population groups, side-effects might again emerge.

An acceptable division of responsibility between states and manufacturers in the event of this happening needs to be established. Can the European Union use its bargaining power to negotiate contracts on behalf of member states, while not forgetting the interests of poor member (and non-member) countries?

None of this is to cast the slightest doubt on the crucial value of a coronavirus vaccine. But whatever our hopes, the licensing of a safe and effective vaccine will still leave difficult issues of accessibility, acceptability and responsibility—which need to be debated.

An earlier version of this article appeared in Italian in Il Manifesto

Stuart Blume and Maurizia Mezza

Stuart Blume is emeritus professor of science and technology studies at the University of Amsterdam and author of Immunization: How Vaccines Became Controversial (Reaktion Books, 2017). Maurizia Mezza is a doctoral candidate in medical anthropology at the University of Amsterdam, focusing on epidemiological studies and pharmacovigilance in relation to HPV vaccination.

Home ・ Politics ・ What when there’s a vaccine?

Most Popular Posts

Boris Johnson, Brexit, Conservative,conservatism Boris Johnson: blustering onPaul Mason
deglobalisation,deglobalization,Davos Getting deglobalisation rightJoseph Stiglitz
schools,Sweden,Swedish,voucher,choice Sweden’s schools: Milton Friedman’s wet dreamLisa Pelling
world order,Russia,China,Europe,United States,US The coming world orderMarc Saxer
south working,remote work ‘South working’: the future of remote workAntonio Aloisi and Luisa Corazza

Most Recent Posts

public services,public service,women,public service workers Public services should not be the victims of inflationIrene Ovonji-Odida
gdp,gross domestic product Let’s count what really mattersJayati Ghosh
green transition,just transition,fossil fuel,energy transition,Ukraine,Russia Ukraine and the geopolitics of the energy transitionBéla Galgóczi and Paolo Tomassetti
energy,efficiency,generation,solar,price,inflation From subsidising energy to reducing dependenceHans Dubois
SPO,Rendi-Wagner,Austria,social democratic,social democrat,social democracy A social-democratic decade ahead?Robert Misik

Other Social Europe Publications

National recovery and resilience plans
The transatlantic relationship
Women and the coronavirus crisis
RE No. 12: Why No Economic Democracy in Sweden?
US election 2020

ETUI advertisement

ETUI/ETUC conference: A Blueprint for Equality

Join us at the three-day hybrid conference ‘A blueprint for equality’ (22-24 June).

The case against inequality has already been strongly articulated. Inequality is not just incidental to a particular crisis but a structural problem created by an economic model. Now is the time to explore what real equality should look like.

As a media partner of this event, Social Europe is delighted to invite you to this three-day conference, organised by the ETUI and ETUC. More than 90 speakers from the academic world, international organisations, trade unions and NGOs will participate, including the economist Thomas Piketty and the European commissioner Nicolas Schmit.


MORE INFOMATION HERE

Eurofound advertisement

Minimum wages in 2022: annual review

Nominal minimum wage rates rose significantly in 2022, compared with 2021. In 20 of the 21 European Union member states with statutory minimum wages, rates increased. When inflation is taken into account, however, the minimum wage increased in real terms in only six member states. If current inflation trends continue, minimum wages will barely grow at all in real terms in any country in 2022.


AVAILABLE HERE

Foundation for European Progressive Studies Advertisement

EU Care Atlas: a new interactive data map showing how care deficits affect the gender earnings gap in the EU

Browse through the EU Care Atlas, a new interactive data map to help uncover what the statistics are often hiding: how care deficits directly feed into the gender earnings gap.

While attention is often focused on the gender pay gap (13%), the EU Care Atlas brings to light the more worrisome and complex picture of women’s economic inequalities. The pay gap is just one of three main elements that explain the overall earnings gap, which is estimated at 36.7%. The EU Care Atlas illustrates the urgent need to look beyond the pay gap and understand the interplay between the overall earnings gap and care imbalances.


BROWSE THROUGH THE MAP

Hans Böckler Stiftung Advertisement

Towards a new Minimum Wage Policy in Germany and Europe: WSI minimum wage report 2022

The past year has seen a much higher political profile for the issue of minimum wages, not only in Germany, which has seen fresh initiatives to tackle low pay, but also in those many other countries in Europe that have embarked on substantial and sustained increases in statutory minimum wages. One key benchmark in determining what should count as an adequate minimum wage is the threshold of 60 per cent of the median wage, a ratio that has also played a role in the European Commission's proposals for an EU-level policy on minimum wages. This year's WSI Minimum Wage Report highlights the feasibility of achieving minimum wages that meet this criterion, given the political will. And with an increase to 12 euro per hour planned for autumn 2022, Germany might now find itself promoted from laggard to minimum-wage trailblazer.


FREE DOWNLOAD

About Social Europe

Our Mission

Article Submission

Membership

Advertisements

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

Social Europe Archives

Search Social Europe

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Follow us on social media

Follow us on Facebook

Follow us on Twitter

Follow us on LinkedIn

Follow us on YouTube